The objectives of national program of antituberculosis during 2001-2010 were to reduce to 50% of incidence and 50% of prevalence in order to reduced the morbidity rate, mortality rate of tuberculosis; early detect 75% of patients with the pulmonary tuberculosis with M. tuberculosis in the sputum; and reduce maximally the risks of drug resistance by successful treating 85% of patients under deployment of strategy of DOTS for 100% of tuberculosis patients
Tuberculosis ; therapeutics

The National development of global DOTS in Vietnam cured 90% of new patients with positive AFB from the tuberculosis and found 80% of estimated patients with tuberculosis the risk index of tuberculosis infection among Vietnamese was 1.7%. According to the estimation of world health organization, in 2001, the population in Vietnam was 79 million inhabitants. The newfound number of tuberculosis were 149,000 (189/100,000 inhabitants). The new estimated number of pulmonary tuberculosis with positive AFB were 67000 (85/100,000 inhabitants). The numbers of pulmonary tuberculosis with M. tuberculosis in the sputum were 53805 (80%). The number of pulmonary tuberculosis with positive AFB received DOTS were 53,561 (80.1%). The number of patients will be disease free were 48,892 (92.6%).
Tuberculosis ; growth & development

Before the era of streptomycine (1952) first used by Selman Walsman, the human history was sunken in thick shadow of tuberculosis. The dead of tuberculosis had dispossessed the life of numerous persons. The discovery of this medication had changed the history. Gerhard Domagk (1939) had rewarded Nobel Prize for his invention to discover protosil the first medication of tuberculosis. DOTS was appreciated as the best option in most efficient intervention. Since May 2001 DOTS enlarged programme was developed world wide
Tuberculosis ; Streptomycin ; Nobel Prize

The basic advantages in the national tuberculosis control programme: policies of our government and party, the public health system and health worker worldwide in whole country, support from International organization. The disadvantages in tuberculosis control programme: survey of epidemiology on tuberculosis were n’t taken in all country, HIV/AIDS epidemic, tuberculosis resistance/ antidrug, lack of health workers for tuberculosis control, manage and control the private health system is limited, shortage finance. The solving method in the future: the stable method is communication activities and immobilization aids from society, finance and human resources serve for tuberculosis control, combination of private healthy that take part in the activities of tuberculosis control, but first of all must maintain a good observation programme for tuberculosis and survey of epidemiology on tuberculosis
Tuberculosis ; Healthy Worker Effect ; health

Background: Recently, microplate almar blue assay has been used commonly in detecting gen related to tuberculosis drug resistance, which provides results after 5-7 days with lower cost compared to traditional methods. Objective: To evaluate the application of microplate almar blue assay for rapid detection of drug resistance of M. tuberculosis strains. Subject and Method: A microplate-based assay which uses Alamar blue reagent - an oxidation reduction dye (MABA), was used for the determination of the anti-tuberculosis drug (isoniazid-INH, rifampicine-RIF, streptomycine-STR and ethabuton=EMB) resistance of 96 M. tuberculosis strains isolated from Vietnamese patients in comparison to those obtained by conversional method. Result: MABA showed to have high sensitivity and specificity in testing the sensitivity to individual anti-tuberculosis drugs (from 82.4% for STR to 93.3% for - INH and from 82.5% for EMB to 98.4% for STR; respectively), as well as for the multi-drug resistant M.tuberculosis (86.4% of sensitivity), highly correlated with the result determined by proportion method. Conclusion: MABA reveals the advantage in shortening test time, in simple performance and lower cost compared with the conversional culture based methods.
Microplate almar blue assay ; M. tuberculosis ; drug resistance